CTCs are dead and ctDNA is the way to go! ctDNA is not only quantitative but also qualitative! The ctDNA technologies are fantastic, but clinical utility depends on effective interventions!

According to this nice JCO Precision Oncology paper: PARPi are effective in prostate cancer w BRCA2 PATHOGENIC variants and less clear with other genes. They also show many pts are treated w PARPi inappropriately on the basis of non-pathogenic variants. ascopubs.org/doi/full/10.12…

Join us in 04/13 for the OncLive.com State of the Science Summit on #BreastCancer! mayocl.in/3ZWquVL

Another study (MAGNITUDE trial in prostate cancer at Journal of Clinical Oncology) showing that ATM carriers do not benefit from PARPi. Same seen in breast at the TBCRC-048 trial. More info at: ascopubs.org/doi/full/10.12…

Sharing the link of this great TEDx talk from a great friend colleague Leo Celi MIT Critical Data raising awareness of bias on machine learning applications in healthcare. app.frame.io/reviews/cdcdcd…

Just out on #ASCODailyNews: we discuss the nuances and favor that ribociclib and abemaciclib over palbociclib in the first line setting for women with ER+ metastatic breast cancer dailynews.ascopubs.org/do/making-sens… ASCO

Final analysis of overall survival in ExteNET. After 8 years of follow up, there was no OS benefit with extended neratinib in the ITT, with an 8-year OS of 90% in both arms. A trend in better OS with neratinib is seen among HR+ patients (OS HR 0.80). ejcancer.com/article/S0959-…

On #MemorialDay, we remember those who lost their lives in service to our country. From the BCRF family to yours, wishing you a peaceful holiday weekend. Photo: Valentino Funghi/Unsplash

Register now to attend OncLive.com's Institutional Perspectives in Cancer virtual event for #BreastCancer, led by Mayo Clinic experts Matthew Goetz and Judy Boughey. See the overview, featured topics and register here: mayocl.in/42vfnUB

I’m glad the FDA went back and made sure olaparib was approved only for the right patients with metastastic prostate cancer, THOSE WITH BRCA mutations. I’m sure we still missing other HRD alterations, so we will keep working on biomarkers.

We compared commercially available HRD biomarkers in terms of response to PARPi in ovarian cancer. BRCA respond the best, Myriad MyChoice and gLOH are comparable. HR proficient should not be on PARPi. Thanks to Laercio DaSilva Leticia Campoverde and others pubmed.ncbi.nlm.nih.gov/37211773/

We’ll need to reconcile NATALEE and MonarchE. Different populations, side effect profile, and duration of therapies. Someone from the audience also brought up the estimated cost of half million dollars for the 3 years of adjuvant ribociclib. Abemaciclib probably not far behind.

Pretty clear after SABCS and ASCO meetings that "HER2 low" is not a biological thing. HER2 0 and HER2 low tumors behave the same clinically. Serial testing shows that lots of HER2 1+/2+ are HER2 0 on later testing, or vice versa.

The non-coding RNA miR-22 promotes EMT transition and metastasis in breast cancer. Inhibiting miR-22 with ASO suppressed mets and prolonged survival in mice. Thanks to collaborators and mentor Ioannis Vlachos for allowing me to help with the bioinformatics! pubmed.ncbi.nlm.nih.gov/37239141/

Check out our new publication about PARPi in ovarian cancer cco.amegroups.com/article/view/1…. I’m so lucky to have met and worked with Felipe Batalini, MD and Laercio DaSilva who are such an inspiration to me. #LatinosInOncology

Our manuscript is out exploring real-world outcomes on PARPi in breast cancer. Patients with germline and somatic BRCA alterations have similar benefit (OS and PFS). A scar-based biomarker of HRD (HRDsig) is associated with favorable outcomes. ascopubs.org/doi/figure/10.…

Many thanks to my wonderful colleagues from BIDMC Nadine Tung MD #GerburgWulf Dana-Farber’s Breast Oncology Center judy garber and #FoundationMedicine Ethan Sokol Geoff Oxnard MD Alexa Schrock et al